190 related articles for article (PubMed ID: 23822636)
1. Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation.
Sato K; Shin MS; Sakimura A; Zhou Y; Tanaka T; Kawanishi M; Kawasaki Y; Yokoyama S; Koizumi K; Saiki I; Sakurai H
Cancer Sci; 2013 Oct; 104(10):1315-22. PubMed ID: 23822636
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and phosphorylations at Ser1039 and Thr1041.
Tong J; Taylor P; Peterman SM; Prakash A; Moran MF
Mol Cell Proteomics; 2009 Sep; 8(9):2131-44. PubMed ID: 19531499
[TBL] [Abstract][Full Text] [Related]
3. TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-{kappa}B-independent survival pathways in tumor necrosis factor alpha signaling.
Nishimura M; Shin MS; Singhirunnusorn P; Suzuki S; Kawanishi M; Koizumi K; Saiki I; Sakurai H
Mol Cell Biol; 2009 Oct; 29(20):5529-39. PubMed ID: 19687304
[TBL] [Abstract][Full Text] [Related]
4. Feedback control of ErbB2 via ERK-mediated phosphorylation of a conserved threonine in the juxtamembrane domain.
Kawasaki Y; Sakimura A; Park CM; Tomaru R; Tanaka T; Ozawa T; Zhou Y; Narita K; Kishi H; Muraguchi A; Sakurai H
Sci Rep; 2016 Aug; 6():31502. PubMed ID: 27531070
[TBL] [Abstract][Full Text] [Related]
5. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling.
Li X; Huang Y; Jiang J; Frank SJ
Cell Signal; 2008 Nov; 20(11):2145-55. PubMed ID: 18762250
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
7. ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression.
Park S; Jung HH; Park YH; Ahn JS; Im YH
Biochem Biophys Res Commun; 2011 Apr; 407(4):680-6. PubMed ID: 21440529
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling.
Huang Y; Kim SO; Jiang J; Frank SJ
J Biol Chem; 2003 May; 278(21):18902-13. PubMed ID: 12642595
[TBL] [Abstract][Full Text] [Related]
9. Transient suppression of ligand-mediated activation of epidermal growth factor receptor by tumor necrosis factor-alpha through the TAK1-p38 signaling pathway.
Singhirunnusorn P; Ueno Y; Matsuo M; Suzuki S; Saiki I; Sakurai H
J Biol Chem; 2007 Apr; 282(17):12698-706. PubMed ID: 17327237
[TBL] [Abstract][Full Text] [Related]
10. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
11. Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation.
Tanaka T; Zhou Y; Ozawa T; Okizono R; Banba A; Yamamura T; Oga E; Muraguchi A; Sakurai H
J Biol Chem; 2018 Feb; 293(7):2288-2301. PubMed ID: 29255092
[TBL] [Abstract][Full Text] [Related]
12. The human transient receptor potential vanilloid 3 channel is sensitized via the ERK pathway.
Vyklicka L; Boukalova S; Macikova L; Chvojka S; Vlachova V
J Biol Chem; 2017 Dec; 292(51):21083-21091. PubMed ID: 29084846
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms for DNA-damaging agent-induced inactivation of ErbB2 and ErbB3 via the ERK and p38 signaling pathways.
Park CM; Kawasaki Y; Refaat A; Sakurai H
Oncol Lett; 2018 Feb; 15(2):1758-1762. PubMed ID: 29434871
[TBL] [Abstract][Full Text] [Related]
14. Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses.
Birtwistle MR; Hatakeyama M; Yumoto N; Ogunnaike BA; Hoek JB; Kholodenko BN
Mol Syst Biol; 2007; 3():144. PubMed ID: 18004277
[TBL] [Abstract][Full Text] [Related]
15. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
16. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type.
VanMeter AJ; Rodriguez AS; Bowman ED; Jen J; Harris CC; Deng J; Calvert VS; Silvestri A; Fredolini C; Chandhoke V; Petricoin EF; Liotta LA; Espina V
Mol Cell Proteomics; 2008 Oct; 7(10):1902-24. PubMed ID: 18687633
[TBL] [Abstract][Full Text] [Related]
17. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
18. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site.
Arteaga CL; Ramsey TT; Shawver LK; Guyer CA
J Biol Chem; 1997 Sep; 272(37):23247-54. PubMed ID: 9287333
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase.
Adelsman MA; McCarthy JB; Shimizu Y
Mol Biol Cell; 1999 Sep; 10(9):2861-78. PubMed ID: 10473632
[TBL] [Abstract][Full Text] [Related]
20. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
Kong A; Calleja V; Leboucher P; Harris A; Parker PJ; Larijani B
PLoS One; 2008 Aug; 3(8):e2881. PubMed ID: 18682844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
